CD72 NANOBODY CAR-T CELLS HAVE POTENTANTITUMOR EFFICACY IN B CELL MALIGNANCIES

被引：0
|
作者：
Temple, W. [1 ]
Nix, M. [2 ]
Wicaksono, G. [2 ]
Wang, D. [3 ]
Phojanakong, P. [3 ]
Steri, V. [3 ]
Hann, B. [3 ]
Hermiston, M. [1 ]
Wiita, A. [2 ]
机构：
[1] Univ Calif San Francisco, Dept Pediat, Div Hematol Oncol, UCSF Benioff Childrens Hosp, San Francisco, CA USA
[2] Univ Calif San Francisco, Lab Med, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
LEUKEMIA RESEARCH | 2022年 / 121卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
010
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [1] CD72 Nanobody-Based CAR-T Cells Have Potent Anti-Tumor Efficacy in B Cell Malignancies
    Nix, Matthew A.
    Temple, William C.
    Karlon, William
    Wang, Donghui
    Phojanakong, Paul
    Steri, Veronica
    Hann, Byron
    Wiita, Arun P.
    BLOOD, 2021, 138
  • [2] Humanized Nanobody Anti-CD72 CAR-T Cells Efficiently Eliminate B-Cell Malignancies Via Improved Affinity for CD72 but Induce Persistent Antigen Downregulation In Vivo
    Temple, William C.
    Wicaksono, Gianina
    Naik, Akul
    Izgutdina, Adila
    Nix, Matthew A.
    Young, Elizabeth
    Phojanakong, Paul
    Serrano, Juan Antonio Camara
    Steri, Veronica
    Salangsang, Fernando
    Wiita, Arun P.
    BLOOD, 2022, 140 : 7394 - 7395
  • [3] Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies
    Temple, William C.
    Nix, Matthew A.
    Naik, Akul
    Izgutdina, Adila
    Huang, Benjamin J.
    Wicaksono, Gianina
    Phojanakong, Paul
    Serrano, Juan Antonio Camara
    Young, Elizabeth P.
    Ramos, Emilio
    Salangsang, Fernando
    Steri, Veronica
    Xirenayi, Simayijiang
    Hermiston, Michelle
    Logan, Aaron C.
    Stieglitz, Elliot
    Wiita, Arun P.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (11)
  • [4] Affinity Matured CD72 CAR-T Improves Efficacy Versus Low Antigen Density B-Cell Non-Hodgkin Lymphoma Models
    Izgutdina, Adila
    Temple, William C.
    Nix, Matthew Andrew
    Geng, Huimin
    Ramos, Emilio
    Naik, Akul
    Larson, Rebecca
    Salangsang, Fernando
    Phojanakong, Paul
    Serrano, Juan Antonio Camara
    Zakraoui, Ons
    Tariq, Isa
    Maus, Marcela V.
    Steri, Veronica
    Wiita, Arun P.
    BLOOD, 2023, 142
  • [5] Enhanced efficacy of CD19/CD22 bispecific CAR-T cells with EAAAK linker on B-cell malignancies
    Ma, Renyuxue
    You, Fengtao
    Tian, Shuaiyu
    Zhang, Tingting
    Tian, Xiaopeng
    Xiang, Shufen
    Wu, Hai
    Yang, Nan
    An, Gangli
    Yang, Lin
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (01) : 64 - 74
  • [6] Efficacy of anti-CD19 CAR-T cell therapy in 10 refractory recurrent B cell malignancies
    包芳
    China Medical Abstracts (Internal Medicine), 2018, 35 (03) : 186 - 187
  • [7] In Vitro-Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies
    Nix, Matthew
    Lin, Hsiu T.
    Geng, Huimin
    Marcoulis, Makeba
    Phojanakong, Paul
    Wang, Donghui
    Steri, Veronica
    Whitman, Jeffrey
    Bapat, Sagar
    Stieglitz, Elliot
    Deucher, Anne
    White, Kristie L.
    Hann, Byron C.
    Wiita, Arun P.
    BLOOD, 2019, 134
  • [8] Surface Proteomics Reveals CD72 as a Target for In Vitro-Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
    Nix, Matthew A.
    Mandal, Kamal
    Geng, Huimin
    Paranjape, Neha
    Lin, Yu-Hsiu T.
    Rivera, Jose M.
    Marcoulis, Makeba
    White, Kristie L.
    Whitman, Jeffrey D.
    Bapat, Sagar P.
    Parker, Kevin R.
    Ramirez, Jonathan
    Deucher, Anne
    Phojanokong, Paul
    Steri, Veronica
    Fattahi, Faranak
    Hann, Byron C.
    Satpathy, Ansuman T.
    Manglik, Aashish
    Stieglitz, Elliot
    Wiita, Arun P.
    CANCER DISCOVERY, 2021, 11 (08) : 2032 - 2049
  • [9] Preclinical development of bispecific CAR-T cells for canine B cell malignancies
    Atherton, Matthew J.
    Rotolo, Antonia
    Mason, Nicola J.
    CANCER RESEARCH, 2022, 82 (12)
  • [10] Selective response of CD5+ B cell malignancies to activation of the CD72 antigen
    Planken, EV
    Van de Velde, H
    Falkenburg, JHF
    Thielemans, K
    Willemze, R
    Kluin-Nelemans, JC
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1998, 87 (01): : 42 - 49
12345